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Abstract
Background: The protease BACE1 (beta-site APP cleaving enzyme) is a major drug target in Alzheimer’s disease.
However, BACE1 therapeutic inhibition may cause unwanted adverse effects due to its additional functions in the
nervous system, such as in myelination and neuronal connectivity. Additionally, recent proteomic studies
investigating BACE1 inhibition in cell lines and cultured murine neurons identified a wider range of neuronal
membrane proteins as potential BACE1 substrates, including seizure protein 6 (SEZ6) and its homolog SEZ6L.
Methods and results: We generated antibodies against SEZ6 and SEZ6L and validated these proteins as BACE1
substrates in vitro and in vivo. Levels of the soluble, BACE1-cleaved ectodomain of both proteins (sSEZ6, sSEZ6L)
were strongly reduced upon BACE1 inhibition in primary neurons and also in vivo in brains of BACE1-deficient
mice. BACE1 inhibition increased neuronal surface levels of SEZ6 and SEZ6L as shown by cell surface biotinylation,
demonstrating that BACE1 controls surface expression of both proteins. Moreover, mass spectrometric analysis
revealed that the BACE1 cleavage site in SEZ6 is located in close proximity to the membrane, similar to the
corresponding cleavage site in SEZ6L. Finally, an improved method was developed for the proteomic analysis of
murine cerebrospinal fluid (CSF) and was applied to CSF from BACE-deficient mice. Hereby, SEZ6 and SEZ6L were
validated as BACE1 substrates in vivo by strongly reduced levels in the CSF of BACE1-deficient mice.
Conclusions: This study demonstrates that SEZ6 and SEZ6L are physiological BACE1 substrates in the murine brain
and suggests that sSEZ6 and sSEZ6L levels in CSF are suitable markers to monitor BACE1 inhibition in mice.
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Background
The β-secretase BACE1 (β-site APP cleaving enzyme) is
a key drug target in Alzheimer’s disease (AD) [1].
BACE1 cleaves the amyloid precursor protein (APP) and
thus catalyzes the first step in generation of the amyloid
β peptide (Aβ) [2–5], which has a critical role in AD
pathogenesis [6]. BACE1 is highly expressed in the
nervous system and contributes to additional physio-
logical processes besides its role in AD, e.g. through
neuregulin-1 cleavage in myelination and CHL1 cleavage
in axon targeting [7–12]. Moreover, several phenotypic
changes were described in BACE1-/- mice, such as
epileptic seizures, schizophrenic symptoms, increased
mortality and altered insulin metabolism, but most of
the BACE1 substrates contributing to these phenotypes
still need to be determined [13]. Their identification and
validation would also allow the estimation of potential
liabilities of BACE inhibitors in AD clinical trials and the
use of BACE1 substrate cleavage products, in addition to
Aβ, as possible companion diagnostics to monitor
BACE1 inhibition in animals and patients.
More than 40 substrate candidates for BACE1 were
identified in recent proteomic studies in murine neurons
or cerebrospinal fluid (CSF), but only a few of them have
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been validated to date with functional or in vitro assays,
including L1, CHL1, ENPP5 and PTPRN2 [12, 14–16].
The three members of the seizure protein 6 (SEZ6)
family, namely SEZ6, SEZ6-like (SEZ6L) and SEZ6-like 2
(SEZ6L2) have been identified as candidate BACE1 sub-
strates in different studies [15, 17], but have not yet been
validated in detail. The SEZ6 family controls synaptic
connectivity and motor coordination in mice [18, 19], but
little is known about the functions of these proteins at the
molecular level. How BACE1-cleavage influences the func-
tion of SEZ6 and SEZ6L has not been investigated so far.
Interestingly, several of the identified BACE1 substrate
candidates were also found to be cleaved by other prote-
ases. As a result, substrate cleavage was only partly
blocked upon BACE1 inhibition or BACE1-deficiency [14,
15], limiting the use of these substrates or their cleavage
products as potential biomarkers to monitor BACE1 in-
hibition in vivo. In contrast, the two type I membrane pro-
teins SEZ6 and its homolog SEZ6L appeared to be almost
exclusively cleaved by BACE1 in neurons [15], making
them potential biomarkers for BACE activity in vivo. The
third family member, SEZ6L2, appeared to be mostly
cleaved by proteases other than BACE1 [15, 17]. After the
proteomic identification of SEZ6 as a BACE1 substrate
candidate, SEZ6 was also shown to undergo reduced
cleavage in BACE1-/- mouse brains [15]. However, the
proteomic data for SEZ6L have not been validated by
other methods and another proteomic study using pancre-
atic cells and tissue failed to confirm SEZ6L as a BACE1
substrate. Instead, that study demonstrated that SEZ6L is
cleaved by the BACE1-homolog BACE2 in pancreas [17].
To resolve whether SEZ6 and SEZ6L are bona fide
BACE1 substrates in brain, we generated monoclonal
antibodies against both proteins and validated SEZ6 and
SEZ6L as BACE1 substrates in murine neurons and
brain. Additionally, SEZ6 and SEZ6L levels at the neur-
onal surface were controlled by BACE1, as demonstrated
by cell surface biotinylation. Finally, we used a whole
proteome analysis of CSF from BACE-deficient mice and
found that the soluble ectodomains of SEZ6 and SEZ6L
in CSF were most strongly reduced among all BACE1
substrates identified, suggesting their use as potential
biomarkers in CSF to monitor BACE1 activity in mice.
Methods
Materials
The following antibodies were used: pAb SEZ6 [18],
newly generated monoclonal SEZ6 and monoclonal
SEZ6L (described below), pAb SEZ6L2 (R&D Systems,
AF4916), pAb SEZ6L (R&D Systems, AF4804), 3D5 (kindly
provided by Robert Vassar), pAb BACE2 (Santa Cruz,
sc-10049), calnexin (Enzo, Stressgen, Farmingdale, NY,
USA, ADI-SPA-860), β actin (Sigma, A5316), LDLR (R&D
system, AF2255), rat mAb HA 3F10 (Roche, 11867423001),
Flag M2 (Sigma, F1804), anti-DYKDDDDK (Biolegend, L5),
anti-V5 (ThermoFisher, R960-25), HRP coupled anti-mouse
and anti-rabbit secondary (DAKO), HRP coupled anti-goat,
anti-rat and anti-sheep (Santa Cruz), biotinylated goat
anti-rat IgG (Vector Laboratories), SULFO-TAG labelled
anti-sheep (MSD, R32AI-1). The following reagents and
media were used: neurobasal medium, HBSS and B27
(Invitrogen), C3 (β-secretase inhibitor IV; Calbiochem,
565788, final concentration 2 μM), DAPT (D5942 Sigma,
final concentration 1 μM), ON-TARGETplus Bace2
siRNA SMARTpool, ON-TARGETplus Non-targeting
Pool (Dharmacon, L-040326-00-0005 and D-001810-
10-05, respectively), FlexiTube GeneSolution siRNA
for Bace1 and AllStars Negative Control siRNA (Qiagen,
GS23821 and SI03650318, respectively).
Mouse strains
The following mice were used in this study: wild type
(WT) C57BL/6NCrl (Charles River), BACE1-/- (Jackson
Laboratory, strain B6.129- Bace1tm1Pcw/J, BACE1 KO),
SEZ6-/- (SEZ6 KO) [18], SEZ6 family triple knockout
(TKO) mice lacking SEZ6, SEZ6L and SEZ6L2 [19] and
SEZ6L2-/- (SEZ6L2 KO, bred from SEZ6 family TKO
[19]). For the CSF experiments the following mice were
used: WT, single BACE1-/- (BACE1 KO), single
BACE2-/- (BACE2 KO), double BACE1-/- BACE2-/-
(BACE DKO) knockout mice [20]. All mice were on a
C57BL/6 background and were maintained on a 12/12 h
light-dark cycle with food and water ad libitum.
Antibody production in rat
Monoclonal antibodies against murine SEZ6 (clone 14E5,
IgG1) and murine SEZ6L (clone 21D9, IgG2a) were gener-
ated using standard procedures [21]. Briefly, a cDNA
(HIS-mmSEZ6-HIS) was generated encoding murine
(mus musculus) SEZ6 ectodomain (mmSEZ6, aa: 29-869,
lacking the endogenous signal peptide) with an N- and C-
terminal HIS tag, fused to an N-terminal CD5 signal pep-
tide. The CD5 signal peptide allows for efficient secretion
of the recombinant protein and is removed upon expres-
sion by signal peptidase, yielding HIS-mmSEZ6-HIS. The
other cDNA (mmSEZ6L-1xStrepII) encoded murine
SEZ6L ectodomain with its endogenous signal peptide
(mmSEZ6L, aa: 1-812) and a C-terminal 1xStrepII tag.
cDNA constructs were expressed in HEK293T cells and
recombinant proteins were purified from the supernatant
and used for immunization of rats.
Immunohistochemistry
DAB immunostaining: Brains from 4 % paraformalde-
hyde perfusion-fixed SEZ6 TKO (n = 4) and WT (n = 7)
adult mice were cryosectioned and underwent sequential
incubation in BLOXALL (Vector Laboratories), 4 %
Bovine Serum Albumin (BSA, Sigma Aldrich) and 0.1 %
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Triton X-100 (Sigma Aldrich) in phosphate buffered
saline (PBS), and avidin/biotin (Avidin/Biotin Blocking
Kit, Vector Laboratories). Sections were incubated over-
night with monoclonal rat anti-SEZ6 or SEZ6L primary
antibodies diluted in 2 % BSA and 0.3 % Triton X-100 in
PBS. Sections were washed with PBS, incubated with
biotinylated goat anti-rat IgG (Vector Laboratories) and
processed using the VECTASTAIN ABC Kit (Vector
Laboratories) and ImmPACT DAB peroxidase substrate
as chromogen (Vector Laboratories) according to manu-
facturer’s instructions. Some sections were counterstained
with haematoxylin. Primary or secondary antibodies were
omitted on sections in each experiment to confirm stain-
ing specificity. Low power images were acquired on a
Mirax slide scanner and high power images were acquired
at 63× magnification on a Zeiss Axio microscope.
Molecular biology
pcDNA3.1/HA-SLIC-Flag-mmSEZ6 was generated clon-
ing full-length Mus musculus SEZ6, transcript variant 1
(Uniprot Q7TSK2-1) without signal peptide in pcDNA3.1
vector using Gibson assembly protocol as previously
described [14]. The signal peptide of SEZ6 was replaced
by the CD5 signal peptide, followed by a short tag
resulting from sequence and ligase independent cloning
(SLIC) [22], and an HA tag (YPYDVPDYA). A FLAG
tag (DYKDDDDK) was cloned to the C terminus of the
protein. pcDNA3.1/HA-SLIC-Flag-empty was used as
control. pcDNA3.1/Flag-V5-hSEZ6-HA was generated
cloning full-length Homo sapiens SEZ6, transcript
variant 1 (Uniprot Q53EL9-1) into pcDNA3.1 vector.
Following the endogenous signaling peptide, a Flag and
V5 (PIPNPLLGLDST) tag were inserted, separated by a
10 amino acid glycine/serine linker sequence. An HA
tag was cloned to the C terminus of the protein.
Transfection and stable line generation
HEK293T stably expressing pcDNA3.1/HA-SLIC-Flag-
mmSEZ6 or pcDNA3.1/HA- SLIC-Flag-empty as control
were generated and cultured as previously described
[14]. Cells were seeded in plates coated with Poly-D-
lysine (Sigma, P6407). After 24 h medium was replaced
with fresh medium supplemented with either C3, DAPT
or DMSO as control. Collection of supernatants and cell
lysates (described below) was done after 24 h. MIN6
were cultured in the same conditions, supplementing
the medium with 2 mM L-glutamine and 50 μM β-
mercaptoethanol (all from Invitrogen). Cells were
transfected with 10 nM of BACE1, BACE2 and respect-
ive control siRNA using Lipofectamine RNAiMAX
(Invitrogen, 13778-150), according to manufacturer’s
instructions. Forty-eight hours post transfection,
medium was replaced and cells were incubated for 24 h
before collection of supernatants and cell lysis.
For drug inhibition studies, MIN6 cells were trans-
fected with pcDNA3.1/Flag-V5-hSEZ6-HA as described
above. Stable cell lines were generated using Geneticin
(Gibco) selection pressure (800 μg/ml). MIN6 cells sta-
bly expressing Flag-V5-SEZ6 were seeded at a concen-
tration of 300,000 cells/well in Falcon 24-well tissue
culture plates (Corning, 353047). After 72 h, the medium
was removed and replaced with fresh medium containing
BACE inhibitors. Cells were treated with a nonselective
BACE inhibitor (Compound A: (4aR,6R,8aS)-8a-(2,4-
difluorophenyl)-6-(3-methylisoxazol-5-yl)-4a,5,6,8-tetrahy-
dro-4H-pyrano[3,4-d] [1, 3] thiazin-2-amine [23], and 2
BACE1-selective inhibitors (Compound B: (5S)-2-amino-
5-(2,6-diethyl-4-pyridyl)-3-methyl-5-(3-pyrimidin-5-ylphe
nyl)imidazol-4-one (AZD3839) [24] or Compound C:
(5S)-2-amino-5-(2,6-diethyl-4-pyridyl)-3-methyl-5-(3-pyri-
midin-5-ylphenyl)imidazol-4-one [25]. After 24 h of drug
incubation, medium was removed, centrifuged to remove
floating cells/cell debris (4000xg, 10 min), and analyzed
for soluble shed Flag-V5-hSEZ6 as described below. For
evaluation of endogenous SEZ6L shedding, wild-type
MIN6 cells were seeded as above, and medium was re-
placed with drug-containing Opti-MEM (Gibco). After
24 h of drug exposure, Opti-MEM was removed and cen-
trifuged to remove cell debris.
Cellular Aβ assay
Cellular activity was assessed using the human SK-N-
BE(2) neuroblastoma cell line expressing the wild-type
amyloid precursor protein (hAPP695). BACE inhibitors
described above were diluted and added to the cells, in-
cubated for 18 h, and then measurements of Aβ42 were
taken. Aβ42 was measured by a sandwich αlisa assay
using biotinylated antibody (AbN/25) attached to
streptavidin-coated beads and antibody (cAb42/26) con-
jugated acceptor beads. In the presence of Aβ42, the
beads come into close proximity. The excitation of the
donor beads provokes the release of singlet oxygen mol-
ecules that triggers a cascade of energy transfer in the
acceptor beads, resulting in light emission. Aβ42 was
quantified on an EnVision Multimode plate reader (Per-
kin Elmer) with excitation at 650 nm and emission at
615 nm.
Enzymatic BACE1 and BACE2 assay
Primary BACE1 and BACE2 enzymatic activity was
assessed by a FRET assay using an amyloid precursor
protein (APP) derived 13 amino acids peptide contain
the “Swedish” Lys-Met/Asn-Leu mutation of the APP β-
secretase cleavage site as a substrate (Bachem, M-2465)
and soluble BACE1(1 − 454) (Aurigene, Custom made)
or soluble BACE2 (Enzo, BML-SE550). The APP peptide
substrate (Mca-SEVNLDAEFRL(Dnp)RR-NH2) contains
two fluorophores: 1) (7-methoxycoumarin-4-yl) acetic
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acid (Mca), a fluorescent donor with excitation wave-
length at 320 nm and emission at 405 nm and, 2) 2,4-
dinitrophenyl (Dnp), a proprietary quencher acceptor. An
increase in fluorescence is linearly related to the rate of
proteolysis. BACE1 or BACE2 were incubated with
substrate and the inhibitor for 120 min in a 384-well plate.
The amount of proteolysis is measured by fluorescence
measurement in the Fluoroskan microplate fluorometer
(Thermo Scientific). For the low control, no enzyme was
added to the reaction mixture.
Mesoscale (MSD) detection of sFlag-V5-SEZ6 and sSEZ6L
Detection of Flag-V5-SEZ6 and SEZ6L was done in
Mesoscale Discovery MULTI-ARRAY 96-well plates
(L15XA-3 or L15XB-3 respectively). sFlag-V5-SEZ6 was
quantified using anti-DYKDDDDK Tag capture antibody
(L5, Biolegend, 10 μg/ml), mouse monoclonal anti-V5
Epitope Tag detection antibody (R960-25, ThermoFisher,
1:20000 dilution) and SULFO-TAG labeled Protein A
(1:4000 dilution) for anti-mouse quantification. SEZ6L
was quantified by coating 30 μl of Opti-MEM medium
diluted 1:25 in PBS to MSD High Bind plates overnight
at 4 °C, followed by detection with 25 μl of R&D System
anti-SEZ6L (AF4804, 2 μg/ml) and SULFO-TAG labeled
Anti-Sheep antibody (MSD, R32AI-1, 1 μg/ml). For both
assays, blocking and antibody dilutions were done in
0.1 % Blocker™ Casein (ThermoFisher) in PBS. Detection
was done using 2× concentration of Read Buffer T
(MSD, R92TC-1). Data were transformed to 0–100 %
activity based on low controls (2.5 μM nonselective
BACE inhibitor with nM potency) and high controls
(0.02 % DMSO) within the same plate. IC50s were calcu-
lated in Graphpad Prism using the four parameter variable
slope nonlinear fit model. All curves are based on
biological replicates with at least two technical replicates.
Isolation of primary neurons
Neurons from WT mice were isolated at E15/E16 and
cultured as described previously [26]. After 5 days in vitro
(DIV), neurons were washed with PBS and medium was
replaced with fresh neurobasal supplemented with C3 or
DMSO as control. After 48 h (7 DIV), supernatants from
neurons were collected and cells were lysed.
Cell lysate preparation
Supernatants from neurons, HEK293T and MIN6 cells
were collected and cells were lysed as described
previously [14]. Protein concentrations were quanti-
fied with an BCA assay (Uptima Interchim, UP95425)
and 15–20 μg of total neuronal lysate, 8–10 μg of
HEK293T lysate and 15–20 μg of MIN6 lysate were
used for Western Blot analysis.
Brain fractionation
Brains were isolated from P7 BACE1 KO mice and WT
littermates. SEZ6 KO, SEZ6L2 KO and SEZ6 TKO and
WT brains were collected from 4 to 5 month old male
mice. All brains were processed as previously described
[15]. Protein concentrations were quantified with an
BCA assay (Uptima Interchim, UP95425) and 15–20 μg
of total protein were used for Western Blot analysis.
Murine CSF sampling
CSF was extracted from single BACE1 KO, BACE2 KO,
BACE DKO mice and WT controls according to a previ-
ously described protocol [27]. CSF was put into a 0.5 ml
LoBind tube (Eppendorf), centrifuged for 5 min at 800 ×
g, and transferred to a fresh tube and frozen at −80 °C.
For mass spectrometric analysis 7 WT and 7 BACE DKO
were sampled and 5 μl of each CSF sample was used.
Immunoblots for the analysis of murine CSF were
performed using 5 or 4 μl of CSF.
Western blot analysis
Samples were boiled for 5 min at 95 °C in Laemmli buffer.
For the detection of SEZ6L, Laemmli buffer without disul-
fide bridge reducing agents such as β-mercaptoethanol was
used. Samples were separated on 8 % SDS-polyacrylamide
gels. Schägger gels were used for the detection of C-
terminal fragments (16.5 % separation gel, 10 % spacer gel
[28]). PVDF membranes (Millipore) were incubated with
primary antibody for 1–2 h at room temperature or at 4 °C
overnight. After incubation with secondary antibody at
room temperature for 1 h, membranes were developed
with ECL prime (GE Healthcare, RPN2232V1).
Deglycosylation assay
40 μg of neuronal lysate were treated with endoglycosi-
dase H (Endo H, New England Biolabs, P0702), or
Peptide-N-Glycosidase (PNGase F, New England Biolabs,
P0704) according to the manufacturer’s protocol. For
SEZ6L, non-reducing conditions were used (denaturation
buffer was with 5 % SDS but no DTT). Afterwards, the
samples were separated on 8 % SDS-polyacrylamide gel.
Surface biotinylation
At 7 DIV, neurons were biotinylated with EZ-Link™ Sulfo-
NHS-Biotin (ThermoFisher, 21217) according to manu-
facturer’s protocol. Quenching was done with ammonium
chloride (50 mM) and BSA (1 %) in PBS and lysis with
SDS lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl,
2 mM EDTA, 1 % SDS). RIPA buffer (10 mM Tris-HCl
pH 8, 150 mM NaCl, 2 mM EDTA, 1 % Triton, 0.1 %
sodium deoxycholate, 0.1 % SDS) was used to dilute the
samples. After sonication, protein concentrations were
quantified and 80 μg of total lysate were incubated with
25 μl of High Capacity Streptavidin Agarose Resin
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(ThermoFisher, 20361), mixed overnight at 4 °C. Beads
were washed in RIPA buffer and bound proteins were
eluted by boiling at 95 °C in Laemmli buffer supple-
mented with 3 mM biotin. Eluted proteins were sepa-
rated on 8 % SDS-polyacrylamide gel and Western
blotting was performed.
BACE1 in vitro digestion and mass spectrometric cleavage
site determination
The murine SEZ6 peptide AASLDGFYNGRSLDVAKA-
PAASSAL (PSL Peptide Specialty Laboratories GmbH,
Germany) was resuspended in LC-MS grade water
(Chromasolv, Sigma Aldrich, Germany) and 40 μg of
peptide were used to determine the cleavage site. Pep-
tides were incubated with recombinant BACE1 with or
without C3 inhibitor in 50 mM sodium acetate buffer
pH 4.4 from 4 to 16 h as previously described [29].
Samples from the peptide cleavage assay were analyzed
by LC-MS/MS. An amount of 500 fmol with respect to
the starting material of the synthetic peptide was
injected. Samples were separated on a nanoLC system
(EASY-nLC 1000, Proxeon – part of Thermo Scientific,
US; PRSO-V1 column oven: Sonation, Germany) using
an in-house packed C18 column (30 cm × 75 μm ID,
ReproSil-Pur 120 C18-AQ, 1.9 μm, Dr. Maisch GmbH,
Germany) with a binary gradient of water (A) and aceto-
nitrile (B) containing 0.1 % formic acid at 50 °C column
temperature and a flow of 250 nl/min (0 min, 8 % B;
25:00 min, 35 % B; 30:00 min, 95 % B; 40:00 min, 95 %
B). The nanoLC was coupled online via a nanospray flex
ion source (Proxeon – part of Thermo Scientific, US) to
a Q-Exactive mass spectrometer (Thermo Scientific,
US). The five most intense ions exceeding an intensity of
1.0 × 104 were chosen for collision induced dissociation.
The dynamic exclusion was reduced to 1 s and the m/z
values of the proposed cleavage products were put on an
inclusion list to get high quality MS/MS spectra.
MS raw data of the peptide cleavage assay were used
to check for m/z values of possible cleavage products.
Quantification was done by calculating the area under
the curve of cleavage products using extracted ion chro-
matograms. Peak areas of the synthetic peptide incu-
bated with BACE1 were compared with the control
incubations of BACE1 and C3 as well as without BACE1.
The identity of cleavage products was verified by a data-
base search against the sequence of the synthetic peptide
with Maxquant [30]. Non-specific cleavage was applied
to identify cleavage products by tandem MS spectra.
Mass spectrometric analysis of CSF samples
Seven WT and seven BACE DKO CSF samples were
used for mass spectrometric analysis. A volume of 5 μL
of CSF per sample was subjected to proteolytic digestion
in 50 mM ammonium bicarbonate with 0.1 % sodium
deoxycholate (Sigma Aldrich, Germany). Disulfide bonds
were reduced by addition of 2 μL 10 mM dithiothreitol
(Biomol, Germany). Cysteine residues were alkylated by
addition of 2 μL 55 mM iodoacetamide (Sigma Aldrich,
Germany). Proteolytic digestion was performed by
consecutive digestion with LysC (0.1 μg; 4 h) and trypsin
(0.1 μg; 16 h) at room temperature (Promega, Germany).
Samples were acidified by adding 4 μL of 8 % formic
acid (Sigma Aldrich, Germany) and 150 μL of 0.1 %
formic acid (Sigma Aldrich Germany). Precipitated
deoxycholate was removed by centrifugation at
16,000 g for 10 min at 20 °C. Proteolytic peptides were
desalted by stop and go extraction (STAGE) with C18
tips [31], dried by vacuum and dissolved in 20 μL 0.1 %
formic acid.
Samples were analyzed with the same LC-MS/MS
method as described for the BACE1 in vitro digestion
assay with a longer gradient (0 min, 2 % B; 3:30 min, 5 %
B; 137:30 min, 25 % B; 168:30 min, 35 % B; 182:30 min,
60 % B; 185 min, 95 % B; 200 min, 95 % B).
Full MS spectra were acquired at a resolution of
70,000. The top ten peptide ions exceeding an intensity
of 1.5 × 104 were chosen for collision induced dissoci-
ation. Fragment ion spectra were acquired at a reso-
lution of 17,500. A dynamic exclusion of 120 s was used
for peptide fragmentation.
MS data analysis of CSF samples
The data were analyzed with Maxquant software (max-
quant.org, Max-Planck Institute Munich) version
1.5.3.12 [30]. The MS data were searched against a
reviewed canonical fasta database of Mus musculus
from UniProt (download: January 26th 2016, 16758 en-
tries). Trypsin was defined as protease. Two missed
cleavages were allowed for the database search. The
option first search was used to recalibrate the peptide
masses within a window of 20 ppm. For the main
search, peptide and peptide fragment mass tolerances
were set to 4.5 and 20 ppm, respectively. Carbamido-
methylation of cysteine was defined as static modifica-
tion. Acetylation of the protein N-term as well as
oxidation of methionine were set as variable modifica-
tions. False discovery rate for both peptides and
proteins was adjusted to less than 1 % using a target
and decoy approach (concatenated forward/reverse
database). Only unique peptides were used for quanti-
fication. Label-free quantification (LFQ) of proteins
required at least two ratio counts of unique peptides.
The LFQ intensity values were log2 transformed and
a two-sided Welch’s t-test was used to evaluate the
significance of proteins with changed abundance between
KO and WT animals. A p-value less than 5 % was set as
significance threshold.
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Statistical tests
Statistical differences for Western Blot experiments were
determined using two-tailed Mann-Whitney test
(GraphPad Prism Software, San Diego, CA, USA). In
Fig. 7, one-way ANOVA followed by two-tailed Stu-
dent’s t-Test, was used for Western Blot quantification.
Graphs show mean ± SEM.
Results
Validation of new monoclonal antibodies against SEZ6
and SEZ6L
To validate SEZ6 and SEZ6L as BACE1 substrates, rat
monoclonal antibodies against both proteins were gener-
ated. They were first tested in immunoblots using mem-
brane fractions from mouse brains. As a control, the
third family member, SEZ6L2, was also analyzed, using a
commercial antibody. To ensure the specificity of the
immunoblot signals, brains from wild type (WT) as well
as from SEZ6-/- (SEZ6 KO) or SEZ6L2-/- (SEZ6L2 KO)
mice were used. As SEZ6L-/- mouse brains were not
available, brains from mice lacking all three SEZ6 family
members (SEZ6-/-, SEZ6L-/-, SEZ6L2-/-; triple knock-
out, TKO [16]) were used instead.
In WT brains the SEZ6 antibody detected a major
band at 170 kDa and a band of minor intensity at
150 kDa (Fig. 1a). Importantly, both bands were absent
in SEZ6 KO and TKO brains, but were clearly visible in
SEZ6L2 KO brains, demonstrating the specificity of the
SEZ6 antibody. Because SEZ6 has 10 predicted N-
glycosylation sites [32], we next determined whether the
two SEZ6 bands differ in their extent of glycosylation. In
order to detect both the major and the minor band more
intensively, a SEZ6 polyclonal antibody was used. En-
dogenous SEZ6 from neuronal lysates was deglycosyl-
ated in vitro using peptide N-glycosidase F (PNGaseF),
which removes all N-linked sugars, or endoglycosidase
H (EndoH), which only removes high-mannose sugars
but not complex glycosylated sugars. PNGaseF induced a
band shift and lowered the apparent molecular weight of
both SEZ6 bands to 155 and 135 kDa, respectively (Fig. 1b).
This demonstrates that SEZ6 is N-glycosylated. How-
ever, the fact that still two distinct SEZ6 bands – and
not just one - were visible demonstrates that both
protein forms must differ by an additional post-
translational modification other than N-glycosylation.
This is likely to be O-glycosylation as SEZ6 was found
to be O-glycosylated in a proteomic study identifying
O-glycosylated proteins [33]. Similar to PNGaseF,
EndoH induced a band shift of the 150 kDa band, but
did not induce a major shift of the 170 kDa band
(Fig. 1b). This reveals that the 170 kDa band contains
complex sugars (referred to as mature SEZ6), whereas
the 150 kDa band (referred to as immature SEZ6),
contains only high-mannose sugars.
The SEZ6L antibody detected one major band at
160 kDa and a very weak band at 130 kDa (Fig. 1a). Both
bands were not detected in the SEZ6 TKO samples,
while they showed unchanged intensity in WT, SEZ6
KO and SEZ6L2 KO brains, thus confirming the specifi-
city of the antibody for SEZ6L. Similar to SEZ6, the
major SEZ6L band at 160 kDa was complex N-
glycosylated. The glycosylation was removed with PNGa-
seF, but not with EndoH (Fig. 1b). The 130 kDa band of
SEZ6L was not consistently detected in the deglycosyla-
tion experiments, but may represent the immature form,
similar to SEZ6.
As a control, SEZ6L2 expression was detected in WT
and SEZ6 KO brains, but was absent in SEZ6L2 KO and
SEZ6 TKO brains (Fig. 1a). Notably, in brains deficient
in SEZ6 or SEZ6L2, levels of the other family members
were not significantly altered (Fig. 1a), revealing that
there are no compensatory changes in protein levels at
least for deficiency of SEZ6 and SEZ6L2.
Taken together, these results demonstrate that SEZ6
and SEZ6L are N-glycosylated proteins and that the
newly generated antibodies specifically detect endogen-
ous SEZ6 and SEZ6L.
In WT adult mouse brains SEZ6 protein was local-
ized to a number of brain regions including the neo-
cortex and hippocampus (Fig. 1c), with particularly
strong immunoreactivity in the striatum and olfactory
tubercle (not shown). In the cortex SEZ6 was localized
to neuronal cell bodies and processes, predominantly
in layers V and VI (Fig. 1c). In the hippocampus, SEZ6
was localized to CA1 pyramidal neuron cell bodies and
dendrites, CA2 and a subset of CA3 neurons, and
sparsely labeled neurons in the dentate gyrus which
resemble interneurons.
SEZ6 immunostaining was completely absent in SEZ6
TKO brain sections (Fig. 1c) and in SEZ6 KO brain
sections (data not shown).
Similarly, SEZ6L immunoreactivity (Fig. 1d) appeared
strong in the neocortex and hippocampus, and protein
localization in these areas was consistent with SEZ6L
mRNA expression in the Allen Mouse Brain Atlas [34].
SEZ6L localized to pyramidal neurons throughout the
cortex, particularly the apical dendrites (Fig. 1d), and
appeared relatively lower in layer IV and VI. All regions
of the hippocampus displayed immunoreactivity for
SEZ6L (Fig. 1d) although staining was less prominent in
neuronal soma than the SEZ6 staining (Fig. 1c). SEZ6L
staining was observed in other brain regions including
the cerebellum and septal nuclei (data not shown).
SEZL6 immunostaining was completely absent in SEZ6
TKO brain sections (Fig. 1d).
Taken together, the newly generated antibodies specific-
ally detect endogenous SEZ6 and SEZ6L by immunohisto-
chemistry as well as Western Blot.
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BACE1 cleavage of SEZ6 and SEZ6L in primary neurons
and mouse brain
As a result of BACE1 cleavage, the soluble ectodomains
of SEZ6 and SEZ6L (sSEZ6 and sSEZ6L) should be shed
into the conditioned medium of primary neurons and
into the extracellular space in mouse brains (Fig. 2a).
However, when BACE1 is inhibited or deleted, sSEZ6
and sSEZ6L might be absent or strongly reduced. In fact,
treatment of primary neurons with the established
BACE1 inhibitor C3 (also known as BACE1 inhibitor
IV) [35] strongly reduced sSEZ6L levels compared to the
control treatment with a concomitant moderate increase
of full-length SEZ6L levels in the cell lysate (Fig. 2b).
Likewise, in P7 BACE1 KO mouse brains sSEZ6L was
strongly reduced in the diethylamine soluble DEA brain
fraction, while full-length SEZ6L was increased in the
membrane fraction (Fig. 2c). In agreement with our pre-
vious study on SEZ6 [15], similar results were obtained
for sSEZ6 and full-length SEZ6 both in C3-treated
neurons and in BACE1 KO mouse brains (Fig. 2b and c).
Taken together, these results reveal that ectodomain
shedding of sSEZ6 and sSEZ6L requires BACE1 activity
both in primary neurons and in mouse brains.
BACE1 cleavage of SEZ6 and SEZ6L in pancreatic MIN6 cells
A previous proteomic study showed that SEZ6L was
cleaved by BACE2, but not by BACE1 in the pancreatic
β-cell line MIN6 [17], which is different from our find-
ings in neurons and brain. SEZ6 was not detected in that
study. To investigate whether the same differences can
Fig. 1 Specificity of SEZ6 and SEZ6L monoclonal antibodies. a Membranes from mouse brains were probed with the indicated antibodies against
SEZ6, SEZ6L, SEZ6L2 or calnexin. Brains were collected from wild type (WT), SEZ6-/- (SEZ6 KO), SEZ6L2-/- (SEZ6L2 KO) or triple knock-out (TKO)
mice lacking SEZ6, SEZ6L and SEZ6L2. b Lysates from primary neurons were treated with peptide N-glycosidase F (PNGaseF) or endoglycosidase
H (EndoH) and blotted for SEZ6 and SEZ6L. For SEZ6, a polyclonal antibody was used in the deglycosylation experiment. * indicates mature SEZ6,
** indicates immature SEZ6. c, d Immunohistochemistry of TKO and WT brains using antibody against SEZ6 (c) or SEZ6L (d)
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be observed for SEZ6, we used the same cell line MIN6
and knocked-down BACE1 or BACE2 with siRNAs
(Fig. 3a). As a control, cleavage of SEZ6L was also moni-
tored. In agreement with the previous study [17],
sSEZ6L was reduced upon knock-down of BACE2, but
not of BACE1. Interestingly, sSEZ6 was also not reduced
upon knock-down of BACE1, but mildly reduced upon
knock-down of BACE2. This shows that both SEZ6 and
SEZ6L are not substrates for BACE1 in the pancreatic
cell line. Full-length SEZ6 and SEZ6L levels were
increased upon BACE2 knock-down, in line with the re-
duced cleavage of both proteins (Fig. 3a). Taken together,
this demonstrates that both SEZ6 and SEZ6L are cleaved
by different proteases in a tissue-specific manner. One
possible scenario might be that the tissue-specificity
reflects the relative amounts of BACE1 and BACE2 in
different tissues. For example, BACE1 – which was the
major SEZ6 and SEZ6L protease in neurons – was found
to be expressed at higher levels in neurons compared to
MIN6 cells (Additional file 1: Figure S1). The opposite
was seen for BACE2, which was the primary protease
cleaving SEZ6 and SEZ6L in MIN6 cells. This tissue- spe-
cificity is reminiscent of two other BACE1 substrates, APP
and L1, which are mostly cleaved by BACE1 in neurons,
but by ADAM10 in non-neuronal cells [15, 36–39].
The cleavage of SEZ6 and SEZ6L in MIN6 cells by
BACE2, but not BACE1, was further evaluated using
nonselective (inhibiting both BACE1 and BACE2) and
BACE1-selective pharmacological inhibitors by assessing
shedding of SEZ6 and SEZ6L in MIN6 cells. Because
SEZ6 is expressed at low levels in MIN6 cells (Add-
itional file 1: Figure S1), human SEZ6 tagged with an N-
terminal Flag- and V5-tag (Flag-V6-hSEZ6) was mildly
overexpressed in MIN6 cells. To validate the efficacy of
BACE1 inhibition, Aβ42 (a BACE cleavage product of
APP) was measured in the SK-N-BE(2) neuroblastoma
cell model, and sFlag-V5-hSEZ6 and endogenous
sSEZ6L in MIN6 cells. IC50s for the released substrate
cleavage products (sFlag-V5-SEZ6 sSEZ6L) were com-
pared with IC50s determined in enzymatic BACE1 and
BACE2 assays. Cleavage of Aβ42 and sFlag-V5-SEZ6 and
sSEZ6L were similar after addition of nonselective BACE
inhibitor A and was consistent with equipotent inhib-
ition of BACE1 and BACE2 in enzymatic assays.
However, cleavage of sFlag-V5-SEZ6 and sSEZ6L was
less impacted than Aβ42 upon inhibition with BACE1-
selective inhibitors (B and C) and followed the enzym-
atic inhibition curves of BACE2 rather than BACE1
(Fig. 3b). This confirms the findings in Fig. 3a and dem-
onstrates that in MIN6 cells SEZ6 and SEZ6L are pre-
dominantly cleaved by BACE2, but not by BACE1.
BACE1 inhibition increases neuronal cell surface levels of
SEZ6 and SEZ6L
The deglycosylation experiment (Fig. 1b) had revealed
that mature SEZ6 and SEZ6L carry complex N-linked
sugars and are resistant to EndoH treatment. Complex
sugars are added as proteins move through the Golgi
apparatus. Thus, the mature forms of SEZ6 and SEZ6L
are likely to be located in late compartments of the
secretory pathway or at the plasma membrane. Indeed,
using cell surface biotinylation the mature, but not the
immature forms of both proteins were detected at the
cell surface of primary neurons (Fig. 4). Treatment with
the BACE inhibitor C3 increased full-length, mature
SEZ6 and SEZ6L in whole cell lysates (Fig. 2b) and also
at the cell surface (Fig. 4). As a control, surface levels of
the LDL-receptor (LDLR), which is a substrate of
ADAM10, but not of BACE1 [38], were not altered upon
BACE inhibition. To demonstrate the specificity of the
surface biotinylation, β-actin was detected in whole
lysates, but strongly reduced in the pull-down of the bio-
tinylated cell surface proteins (Fig. 4), as expected for a
cytoplasmic protein. Taken together, BACE1 activity
negatively controls the levels of SEZ6 and SEZ6L at the
neuronal cell surface and in whole lysates.
BACE1 cleaves SEZ6 within its juxtamembrane domain
Next, we determined the cleavage site of BACE1 within
the juxtamembrane domain of SEZ6 and compared it to
the previously identified cleavage site within its homolog
SEZ6L [15]. In the previous proteomic study which iden-
tified SEZ6 as a BACE1 substrate candidate, several
tryptic peptides of the secreted SEZ6 ectodomain were
identified. The most C-terminal of these peptides
encompassed amino acids 894 to 904 (AASLDGFYNGR)
of murine SEZ6 (Fig. 5a). This was a tryptic peptide end-
ing with arginine (R), but BACE1 preferentially cleaves
C-terminally to leucine or other hydrophobic amino
acids [40]. Thus, the BACE1 cleavage site is likely to be
(See figure on previous page.)
Fig. 2 BACE1 is required for SEZ6 and SEZ6L shedding in primary neurons and mouse brain. a Schematic diagram of SEZ6 and SEZ6L domain
structure and proposed proteolytic processing. b Detection of soluble SEZ6 and SEZ6L ectodomains (sSEZ6 and sSEZ6L) and full-length SEZ6 and
SEZ6L in neuronal supernatant and lysate upon C3 treatment. c Detection of sSEZ6 and sSEZ6L and full-length SEZ6 and SEZ6L in BACE1 KO and
WT brains. Brains were separated into soluble fraction (DEA) and membranes (membrane). Note that in this figure, a different molecular weight
marker has been used compared to Fig. 1. The 148 kDa band corresponds to the band detected at 170 kDa in Fig. 1. The upper band in panel 2C
(*) is due to unspecific signal. Densitometric quantitations of the Western blots are shown, (*; p < 0.05, **; p < 0.01, two-tailed Mann-Whitney
test n = 6)
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located between this tryptic peptide and the transmem-
brane domain (start: leucine 923). To determine this site
precisely, an in vitro peptide assay was used. The 25
amino acid peptide AASLDGFYNGRSLDVAKAPAAS-
SAL (Fig. 5a, amino acids 894 to 918), comprising the
tryptic peptide and ending shortly before the transmem-
brane domain, was incubated in the presence or absence
of recombinant BACE1 with or without the BACE1
inhibitor C3 (Fig. 5b). Full-length peptide and cleavage
fragments were separated by nano liquid chromatog-
raphy and analyzed by high resolution mass spectrom-
etry (nanoLC/MS). The non-cleaved, full-length peptide
eluted from the nLC column at ~ 22 min (Fig. 5b). The
correct sequence was verified by MS/MS-based frag-
mentation (Fig. 5c). Upon addition of BACE1, the full-
length peptide levels were decreased in the chromato-
gram and two additional peptides with elution times
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Fig. 3 BACE2 but not BACE1 cleaves SEZ6 and SEZ6L in a pancreatic β-cell line. a sSEZ6 and sSEZ6L were detected in the supernatant and full-
length SEZ6 and SEZ6L in the lysate of the pancreatic β-cell line MIN6 upon BACE1 and BACE2 knock-down by siRNA (siB1, siB2). As a control,
cells were treated with non-silencing control siRNA (siCon). Densitometric quantitations of the Western blots are shown, (*; p < 0.05, two-tailed
Mann-Whitney test n = 4). b BACE1 (green lines) and BACE2 (blue lines) activity were quantified in enzymatic (solid lines) and cellular (dotted lines)
models after pharmacological inhibition with nonselective (inhibiting both BACE1 and BACE2, compounds B and C) and BACE1-selective inhibitors
(compound A). Soluble Aβ42 as well as sSEZ6 and sSEZ6L were detected in the supernatant of the neuroblastoma cell line SK-N-BE(2) or in the
MIN6 respectively, as indicated. Data were standardized to low and high controls within each assay. Data represent
biological duplicates with two or more technical replicates
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of C3 inhibited the production of both peptides, dem-
onstrating that they are BACE1 cleavage products of
the full-length peptide. The two peptides were identified
as AASLDGFYNGRSL (N-terminal cleavage product,
Fig. 5d) and DVAKAPAASSAL (C-terminal cleavage prod-
uct 2, Fig. 5e) by fragment spectra. Thus, we conclude that
the BACE1 cleavage site in SEZ6 is the peptide bond
between leucine906 and aspartate907 (Fig. 5a). Interest-
ingly, this site comprises the same amino acids in the P1
and P1’ position (L-D) as Swedish mutant APP (Fig. 5a),
which is very efficiently cleaved by BACE1 [4]. The previ-
ously identified cleavage site in SEZ6L [15] is not identical,
but similar to SEZ6, as it also has a hydrophobic amino
acid in the P1 and a negatively charged amino acid in the
P1’ position (Fig. 5a). Moreover, SEZ6 and SEZ6L are both
cleaved at a similar distance from the transmembrane
domain, i.e. 16 and 14 amino acids for SEZ6 and SEZ6L,
respectively (Fig. 5a).
SEZ6 is a substrate for γ-secretase
After initial BACE1 cleavage, the resulting C-terminal,
membrane-bound protein fragments of several mem-
brane proteins, including APP and SEZ6L [17], are
further processed within their transmembrane domains
by γ-secretase, in a process referred to as regulated
intramembrane proteolysis [41] (for schematic overview
see Fig. 2a). The accumulation of C-terminal fragments
upon pharmacological inhibition of γ-secretase with
DAPT can be used to identify γ-secretase substrates [42].
To examine if SEZ6 is also cleaved by γ-secretase, we
generated a human embryonic kidney 293 (HEK293T) cell
line stably expressing murine SEZ6. Due to the lack of an
antibody against the SEZ6 C-terminus, the full-length
SEZ6 construct was tagged with an N-terminal HA and a
C-terminal FLAG epitope tag. The full-length SEZ6 in the
cell lysate and the shed ectodomain (sSEZ6) in the super-
natant were detected by immunoblots in the transfected
cells, but not in control transfected cells (Fig. 6a).
Addition of the BACE inhibitor C3 decreased the sSEZ6
(Fig. 6a), in agreement with the results in neurons (Fig. 2b).
The expected C-terminal fragment arising through
BACE1 cleavage was not detected in control cells without
the γ-secretase inhibitor DAPT, presumably because of its
fast turnover. However, γ-secretase inhibition led to a
strong accumulation of the SEZ6 C-terminal fragment at a
molecular weight of around 13 kDa (Fig. 6b), which is
consistent with the theoretical molecular weight of about
10 kDa for the C-terminal fragment starting at the BACE1
cleavage site and ending with the C-terminal FLAG-tag.
These results indicate that SEZ6 is a γ-secretase substrate.
sSEZ6 and sSEZ6L are detected in murine CSF in
BACE1-dependent manner
Finally, we tested in vivo whether levels of sSEZ6 and
sSEZ6L in murine CSF may be useful biomarkers for
BACE1 activity in vivo. A previous proteomic study
demonstrated that the soluble ectodomains of other
BACE1 substrates, such as APLP1, PLXDC2 and CHL1,
were reduced in the CSF of BACE1-deficient mice [14].
However, sSEZ6 and sSEZ6L were not consistently
detected and could not be quantified in murine CSF,
potentially because their levels were below the detection
limit. Thus, we first improved the method for proteomic
analysis of murine CSF in order to identify and quantify
a larger number of proteins compared to the previous
study. Most BACE1 inhibitors currently tested in clinical
trials for AD are not specific for BACE1, but also inhibit
BACE2. To mimic this situation we applied the im-
proved proteomic method to the analysis of CSF from
seven 4-month old BACE1/BACE2 double knock-out
(BACE DKO) and seven age-matched WT mice.
In our previous protocol for mouse CSF proteomics,































Fig. 4 BACE1 controls neuronal cell surface levels of SEZ6 and
SEZ6L. Primary, murine neurons were treated with the BACE
inhibitor C3 or DMSO as a control. Proteins at the surface were
labeled with biotin and enriched using streptavidin pull-down.
Biotinylated SEZ6 and SEZ6L were detected by immunoblot. As a
control, both proteins were also detected in whole cell lysates. Note,
that only the mature 170 kDa form of SEZ6 was biotinylated at the
cell surface. As a control, the ADAM10 substrate LDL receptor (LDLR)
did not show a change in surface levels upon C3-treatment. As a
further control, the cytosolic protein actin was only detected in
whole lysates, but not among the surface biotinylated proteins
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thiourea [14]. We replaced these nonionic chaotropes
with the mild ionic detergent sodium deoxycholate
(SDC), which has been shown to improve trypsin diges-
tion of membrane proteins [43, 44]. A concentration of
0.1 % SDC was sufficient to improve the digestion effi-
ciency. Triplicates of a pooled mouse CSF sample were
digested with either the urea or the SDC-supported
digestion protocol. The number of identified unique
peptides was 6.6 % lower for the SDC supported proto-
col (Table 1). However, digestion efficiency was strongly
increased which was detected by the 58.1 % lower num-
ber of average missed cleavages per peptide (Table 1).
Additionally, the average number of identified and quan-
tified proteins was 10.3 and 7.5 % higher for the SDC
supported digestion protocol, respectively. Subcellular
locations of proteins quantified in all replicates of SDC
or urea supported digestions were similar (Additional
file 1: Figures S2 and S3). However, the number of quan-
tified membrane proteins was 8.9 % higher for the
samples digested in the presence of SDC (135 vs. 124).
Next, BACE DKO CSF was compared to WT CSF. In
contrast to our previous proteomic study of CSF from
BACE1 deficient mice [14], we were able to quantify SEZ6
and SEZ6L with the optimized protocol (Additional file 2:
Supplementary Data: proteins BACE DKO vs WT CSF).
The levels of several known or proposed BACE1 sub-
strates such as SEZ6, SEZ6L, SCN4B, LRRN1, APLP1,
APLP2, CACHD1 and NLGN4L were significantly re-
duced in BACE DKO CSF (Fig. 7a). Among these proteins,
SEZ6 (DKO/WT= 13 %, p = 5.99E-06) and SEZ6L (DKO/
WT= 20 %, p = 5.10E-05) showed the strongest reduction
as well as the highest statistical significance (Fig. 7a).
Changes in sSEZ6 and sSEZ6L also remained significant,
when applying the Benjamini-Hochberg false discovery
rate adjustment (α = 5 %) to correct for multiple hypoth-
esis testing. In contrary, the third SEZ6 family member,
SEZ6L2, did not show a significantly lower abundance in
BACE DKO CSF, indicating that it is mostly cleaved by
protease other than BACE1 or BACE2 (Fig. 7a).
Interestingly, the interleukin-6 receptor subunit beta
(IL6ST) was quantified in all WT CSF samples by four
unique peptides but in none of the BACE DKO CSF sam-
ples. This indicates that IL6ST may be an additional
BACE1 and/or BACE2 substrate. Another BACE substrate
candidate could be the type-1 transmembrane protein
hephaestin (HEPH), which was significantly reduced by
53 % in BACE DKO CSF. Hephaestin is known to be
expressed in the brain [45]. Additionally, peptide se-
quences of transmembrane and GPI-anchored proteins
(See figure on previous page.)
Fig. 5 Cleavage site determination of SEZ6. a Comparison of BACE1 cleavage sites in the known APP Swedish mutant, in SEZ6 and SEZ6L.
Additionally, the peptide (SEZ6 pep) used for the in vitro assay is aligned. Numbers next to the N- and C-terminal amino acids of the peptide
indicate the amino acid number within the sequence of the full-length protein. Amino acids at the cleavage site are shown in green. Amino acids
of the transmembrane domains are in red. Domains of SEZ6 and SEZ6L are shown with indicated symbols. The most C-terminal tryptic peptide of the
secreted SEZ6 ectodomain detected in our previous study is underlined in black. b Extracted ion chromatogram of full-length peptide incubated with
BACE1, BACE1 plus C3 or without BACE1 showing the peaks of the two cleavage products as well as the full-length peptide. Identification of the
full-length peptide (c), the N-terminal (d) and the C-terminal cleavage product (e) by fragment ion spectra. The mapped y and b fragment ions are





















Fig. 6 SEZ6 is a substrate for γ-secretase. a HEK293T cells were stably
transfected with empty vector (Empty) or SEZ6 expression construct
with an N-terminal HA-tag and a C-terminal FLAG epitope tag. Cells
were treated with C3 or DMSO as a control. sSEZ6 was detected in
the cell supernatant and full-length SEZ6 in the lysate. Calnexin was
used as a loading control. b Cells were treated with DMSO, C3 or
the γ-secretase inhibitor DAPT. The C-terminal SEZ6 fragment was
detected by immunoblot using an anti-FLAG-tag antibody
Table 1 Comparison of urea and SDC supported digestion of
mouse CSF
SDC Urea Difference
Unique peptides 5955.3 6376.7 −6.6 %
Average missed cleavages per peptide 0.26 0.62 −58.1 %
Protein identifications (≥2 unique peptides) 814.0 738.0 +10.3 %
Protein quantifications 847.7 788.3 +7.5 %
Values are averaged over three replicates
Pigoni et al. Molecular Neurodegeneration  (2016) 11:67 Page 13 of 18
were loaded into the bioinformatics software tool QARIP
[46] to check for their position within the protein se-
quences. Peptides were almost exclusively mapped to
extracellular domains of transmembrane proteins (Add-
itional file 3: Tables S1-S6). This indicates that most trans-
membrane proteins in the CSF are derived from
proteolytic shedding and not from contaminating cells.
For SEZ6, SEZ6L and SEZ6L2 only peptides from the
ectodomain were identified (Additional file 3: Table S1).
To validate the proteomic results, reduced abun-
dance of sSEZ6 and sSEZ6L were confirmed using
immunoblots of independent CSF samples (Fig. 7b). In
agreement with the proteomic analysis, sSEZ6 was
nearly completely absent in BACE DKO CSF. The same
reduction was observed in CSF from BACE1 KO, but
not for BACE2 KO mice. This demonstrates that sSEZ6
is generated specifically by BACE1, but not by BACE2
in murine CSF. Likewise, sSEZ6L was strongly reduced
in BACE1 KO CSF. Taken together, these results show
that sSEZ6 and sSEZ6L levels can be used to monitor
BACE1 activity in murine CSF.
Discussion
BACE1 is a major drug target in AD, but has additional
substrates and thus contributes to various biological pro-
cesses [1, 13], which may limit its therapeutic potential.
Recent proteomic studies have identified more than 40
membrane proteins as potential BACE1 substrates [14–16].
However, only few of them have been validated in vitro and
in vivo. Using different techniques, our study validates
SEZ6 and SEZ6L as BACE1 substrates in vitro and in vivo
and demonstrates that, in contrast to other BACE1 sub-
strates, SEZ6 and SEZ6L are nearly exclusively cleaved by
BACE1 and not by other proteases in the brain. Levels of
the soluble ectodomains (sSEZ6, sSEZ6L) were reduced to
less than 10 % of the control levels upon pharmacological
inhibition of BACE1 in primary neurons. Additionally,
SEZ6 and SEZ6L were validated in vivo as BACE1
substrates using brains and CSF from BACE1 KO, BACE2
KO and/or BACE DKO mice. Thus, we propose that in
addition to Aβ and sAPPβ, which are two BACE1 cleavage
products of APP, sSEZ6 and sSEZ6L may be suitable as
biomarkers to monitor BACE1 activity in vivo in CSF.
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Fig. 7 Proteomic analysis of CSF from BACE DKO and WT mice. a Volcano plot of proteomic analysis of BACE1 and BACE2 double knockout
(BACE DKO) and WT mouse CSF. The minus log10 transformed t-test p-values are plotted against the log2 transformed label-free quantification
intensity ratios of BACE DKO and WT CSF for every relatively quantified protein. Proteins with a t-test p-value < 0.05 are shown as red circles.
Already known BACE substrate candidates with a p-value < 0.05 are marked with gray filling. Proteins that remain significant after Benjamini-Hochberg
false discovery rate correction (FDR < 0.05) have bold letters (SEZ6 and SEZ6L). b Detection of sSEZ6 and sSEZ6L in mouse CSF. Densitometric
quantitation of the Western blot is shown, (**; p < 0.01, one-way ANOVA followed by two-tailed Student’s t-Test, n = 3). The dotted line indicates that
the samples were loaded onto the same blot, but not next to each other
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Several other previously identified BACE1 substrates,
such as CHL1, L1, contactin-2, APP and its homolog
APLP2, are not exclusively cleaved by BACE1, but also
by other proteases, including ADAM10 [15, 38]. For
example, the APP homolog APLP2 is cleaved to about
60 % by BACE1 and to 40 % by ADAM10 in neurons,
but the percentages may strongly vary for each substrate
[38]. Additionally, the different proteases may compen-
sate for each other, if one of them is blocked. One
example is APP. BACE1 inhibition increases the
ADAM10 cleavage of APP, such that total APP cleavage
is only mildly reduced [36, 47]. Potentially, this is also
true for the third SEZ6 family member, SEZ6L2, which
shows only moderately reduced shedding upon BACE1
inhibition [15]. A similar compensation does not occur
for SEZ6 and SEZ6L in brain, where total cleavage was
nearly completely abolished upon BACE1 inhibition.
However, in other cell types and tissues both proteins
may be cleaved by proteases different than BACE1. A
previous study reported that in pancreatic cells SEZ6L is
predominantly cleaved by BACE2, but not by BACE1
[17]. We confirm this finding and also extend it to
SEZ6. Importantly, we show that neither SEZ6 nor
SEZ6L are substrates for BACE1 in the pancreatic cell
line, which is in contrast to brain, demonstrating that
SEZ6 and SEZ6L are cleaved by different proteases in a
tissue-specific manner. Precedents for such a tissue-
specific proteolytic cleavage are the BACE1 substrates
CHL1 and L1, which are mostly cleaved by BACE1 in
the nervous system, but by ADAM proteases in non-
neuronal cells [15, 37]. We found opposite expression
patterns of BACE1 and BACE2 in MIN6 cells and in
neurons, which correlated with the tissue-specific cleav-
age of SEZ6 and SEZ6L. Whether the distinct protease
cleavage events also lead to a different functional out-
come for the substrates remains to be investigated. This
is particularly relevant as different proteases may cleave
at distinct peptide bonds and thus generate ectodomains
of different lengths and potentially different functions.
For example, in APP the ADAM10 and BACE1 cleavage
sites are 16 amino acids apart from each other and yield
APP ectodomains with diverging functions [48, 49].
The molecular functions of SEZ6 and SEZ6L are not
yet well understood. The name SEZ6 comes from the
initial finding that SEZ6 expression was upregulated in
cortical murine cells treated with the seizure-inducing
drug pentylene tetrazole [32]. SEZ6 has been genetically
linked to febrile seizures and epilepsy [50, 51], whereas
SEZ6L was associated with bipolar disorder [52]. The
extracellular regions of SEZ6/SEZ6L contain three CUB
(complement subcomponent C1r, C1s /sea urchin em-
bryonic growth factor Uegf / bone morphogenetic
protein 1) and five short consensus repeat domains,
which are protein-binding domains that are also found
in a variety of cell surface receptors. This suggests that
SEZ6/SEZ6L may act as receptors at the cell surface.
Importantly, our study demonstrates that BACE1 cleav-
age negatively regulates SEZ6 and SEZ6L surface levels
in neurons, suggesting that BACE1 may directly control
SEZ6/SEZ6L surface functions. This could be a more
general function of BACE1, because BACE1 also nega-
tively regulates surface levels and/or function of two
other substrates, contactin-2 and CHL1 [12, 15, 53].
However, the function of SEZ6 and SEZ6L may not only
be exerted by the full-length proteins, but also by sSEZ6
and sSEZ6L or even by the C-terminal fragments result-
ing from BACE1 cleavage, as recently found for the
BACE1 substrate CHL1 [12].
Future studies need to address how exactly BACE1
alters SEZ6 and SEZ6L function and whether such alter-
ations contribute to the multiple phenotypes observed in
BACE1-deficient mice. Notably, both BACE1- and SEZ6-
deficient mice have deficits in hippocampal learning para-
digms [18, 54–56] and in motor coordination [18, 57].
Moreover, both mouse lines appear to have reduced levels
of anxiety and/or cognitive deficits [18, 56], reduced gluta-
matergic synapse function and reduced dendritic spine
densities [18, 58]. Given the substantial overlap, at least
some of these phenotypes may result from the reduced
cleavage products of SEZ6/SEZ6L.
Another major outcome of our study is an improved
protocol for efficient proteomic analysis of murine CSF.
While human CSF is available in milliliter quantities, only
approximately 10 μl of murine CSF are obtainable. Here,
we improved the digestion efficiency of murine CSF in
comparison to our previous protocol by using 0.1 % SDC
in 50 mM ammonium bicarbonate as digestion buffer.
This was demonstrated by the strong reduction of the
average missed cleavages per peptide as well as the in-
creased number of identified and quantified proteins
(Table 1). The improved method may be of wide relevance
for studying murine CSF in the context of different neuro-
logical and neurodegenerative diseases. Importantly, the
new workflow allowed the quantification of SEZ6 and
SEZ6L, which were not quantified in the previous study
[14]. The nearly complete absence of sSEZ6 and sSEZ6L
in murine CSF makes both cleavage products suitable
markers to monitor BACE1 inhibition in mice. This may
be particularly useful for determining the target engage-
ment and potential side effects of BACE inhibitors in
animal models. If confirmed in human CSF, sSEZ6 and
sSEZ6L may even be useful as companion diagnostics to
guide BACE inhibitor dosing in individual patients and
monitor BACE1 inhibitor selectivity.
Conclusions
We demonstrate that SEZ6 and SEZ6L are physiological
BACE1 substrates in the murine brain and that, in
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contrast to most other BACE1 substrates, these two pro-
teins are nearly exclusively cleaved by BACE1. Levels of
sSEZ6 and sSEZ6L were strongly reduced upon pharma-
cological inhibition or genetic deficiency of BACE1 in
primary neurons and mouse brain. Additionally, we
developed an improved method for whole proteome
analysis of murine CSF and found that in the CSF of
BACE DKO mice the soluble ectodomains of SEZ6 and
SEZ6L were most strongly reduced among all BACE1
substrates identified, suggesting their use as potential
biomarkers in CSF to monitor BACE1 activity in vivo in
mice.
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